SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Clarification sought from Aurobindo Pharma

05 Mar 2018 Evaluate

The Exchange has sought clarification from Aurobindo Pharma on March 05, 2018 with reference to news flashed on www.moneycontrol.com dated March 05, 2018 quoting ‘US FDA observations - Aurobindo Unit 4 inspected by US FDA from February 12-20 and issues 9 observations.’

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1480.40 -3.00 (-0.20%)
07-May-2026 15:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1835.25
Dr. Reddys Lab 1306.55
Cipla 1362.95
Zydus Lifesciences 941.35
Lupin 2455.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×